Combigene AB Total Liabilities

Latest as of December 2024: Skr4.30 Million SEK ≈ $462.75K USD

Combigene AB total liabilities. Based on the latest financial reports, Combigene AB (COMBI) has total liabilities worth Skr4.30 Million SEK (≈ $462.75K USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Combigene AB (COMBI) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Combigene AB (2012–2024)

Total liabilities of Combigene AB from 2012 to 2024. This chart illustrates how Combigene AB's total liabilities have evolved over time, based on quarterly financial data.

Combigene AB Competitors by Total Liabilities

The table below lists competitors of Combigene AB ranked by their total liabilities.

Company	Country	Total Liabilities
ARK Resources Bhd KLSE:7007	Malaysia	RM41.45 Million
Twin Vee Powercats Co NASDAQ:VEEE	USA	$6.25 Million
Bhakti Agung Propertindo JK:BAPI	Indonesia	Rp292.66 Billion
Intertainment AG XETRA:ITN	Germany	€11.77 Million
Gelteq Limited Ordinary Shares NASDAQ:GELS	USA	$5.92 Million
Ladangbaja Murni PT Tbk JK:LABA	Indonesia	Rp31.52 Billion
Union Pioneer Public Company Limited BK:UPF	Thailand	฿144.96 Million

Liability Composition Analysis (2012–2024)

This chart breaks down Combigene AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see COMBI current and non-current assets.

Liquidity & Leverage Metrics

Combigene AB Total Liabilities Ratios Explained

Combigene AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	17.47	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.06	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.06	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Combigene AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Combigene AB (2012–2024)

The table below shows the annual total liabilities of Combigene AB from 2012 to 2024.

Year	Total Liabilities	Change
2024-12-31	Skr4.30 Million ≈ $462.75K	+3.47%
2023-12-31	Skr4.16 Million ≈ $447.22K	-31.86%
2022-12-31	Skr6.10 Million ≈ $656.32K	-23.21%
2021-12-31	Skr7.94 Million ≈ $854.68K	-0.49%
2020-12-31	Skr7.98 Million ≈ $858.87K	-66.06%
2019-12-31	Skr23.51 Million ≈ $2.53 Million	+60.38%
2018-12-31	Skr14.66 Million ≈ $1.58 Million	+801.06%
2017-12-31	Skr1.63 Million ≈ $175.10K	+100.96%
2016-12-31	Skr809.66K ≈ $87.13K	+17.05%
2015-12-31	Skr691.73K ≈ $74.44K	+18.85%
2014-12-31	Skr582.04K ≈ $62.64K	+1320.21%
2013-12-31	Skr40.98K ≈ $4.41K	-86.18%
2012-12-31	Skr296.58K ≈ $31.92K	--

About Combigene AB

ST:COMBI Sweden Biotechnology

Market Cap

$5.24 Million

Skr48.71 Million SEK

Market Cap Rank

#28415 Global

#623 in Sweden

Share Price

Skr2.46

Change (1 day)

+0.00%

52-Week Range

Skr2.46 - Skr2.46

All Time High

Skr152.75